<DOC>
	<DOC>NCT03106532</DOC>
	<brief_summary>Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma</brief_summary>
	<brief_title>Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma</brief_title>
	<detailed_description>Data collection (electronic case report forms), Data dictionary (MedDRA)</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Low Tension Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>19 years and older, female and male IOP ≤21 mmHg Subject showing open angle finding, glaucomatous optic nerve damage and visual field defects BCVA ≥+0.2 Subject with the disease and surgery history that are not eligible to participate (acute closed angle glaucoma, narrow angle glaucoma, advanced glaucomatous loss, ocular trauma, eye surgery or laser surgery, unstable angina, myocardial infarction, uncontrolled hypertension and diabetes, etc) Subject who can't discontinue contact lenses Subject who can't discontinue topical/systemic IOP lowering medication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>